Abstract：Objective To investigate the clinical effect of Levosimendan combined with Levocarnitine in the treatment of patients with refractory heart failure.Methods From March 2016 to July 2017,60 patients with refractory heart failure treated in our hospital were enrolled as observation subjects.They were randomly divided into observation group and control group by a random number table method,30 cases in each group.The two groups were provided with routine therapeutic measures such as ECG monitoring,oxygen therapy,diuretic,and angiotensin converting enzyme inhibitor and so forth.In the control group,only Levocarnitine used,while in the observation group,Levosimendan was added on the basis of the control group.The clinical efficacy was observed.Differences of the indicators of left ventricular end diastolic diameter(LVEDd),left ventricular end systolic diameter(LVESd),left ventricular ejection fraction(LVEF)and heart index(CI)by echocardiography (ECG)were observed.The incidence of adverse reactions between the two groups was recorded.ResultsThe total therapeutic effectiveness rate in the observation group was significantly higher than that of the control group,and the difference was statistically significant(P＜0.05).Before treatment,the LVEDd,LVESd,LVEF and CI of the two groups were compared,and the differences were statistically significan (P＞0.05).After therapy,the values of LVEDd and LVESd in the observation group was significantly higher than those in the control group,and the differences were statistically significan (P＜0.05).The LVEF and CI were greatly lower than those in the control group,and the differences were statistically significan (P＜0.05).The incidence of adverse reactions was 3.33%in the observation group,while the incidence of adverse reactions in the control group was 10.0%,and the incidence of adverse reactions was compared,and the difference was statistically significan (P＞0.05).Conclusion Levosimendan combined with Levocarnitine in the treatment of refractory heart failure can obtain a favorable clinical effect by effectively improving the patients′cardiac function in high safety,which is worthy of promotion in clinical practice.
Aissaoui N，Morshuis M，Paluszkiewicz L，et al.Comparison of biventricular and left ventricular assist devices for the management of severe right ventricular dysfunction in patients with end-stage heart failure[J].Asaio J，2014，60（4）：400-406.
Rosenzweig EB，Brodie D，Abrams DC，et al.Extracorporeal membrane oxygenation as a novel bridging strategy for acute right heart failure in group 1 pulmonary arterial hypertension[J].Asaio J，2014，60（1）：129-133.
MadiasJE.ComparisonofleadaVR“netQRSarea”and“peakto-peak amplitude”as indices of all limb electrocardiogram leads：Implications for the diagnosis，management，and follow-up in patients with heart failure[J].Med Eng Phys，2015，34（8）：1037-1040.
Rolle VL，Ojeda D，Hern M，et al.Embedding a Cardiac Pulsatile Model Into an Integrated Model of the Cardiovascular Regulation for Heart Failure Followup[J].Ieee Trans Biomed Eng，2016，58（10）：2982-2986.
[15]
González H，Infante O，Pérez-Grovas H，et al.Nonlinear dynamics of heart rate variability in response to orthostatism andhemodialysisinchronicrenalfailurepatients：Recurrence analysis approach[J].Med Eng Phys，2015，35（2）：178-187.
京公网安备 11010502046607号